2015-06-05 18:31:18 UTC

IBD Treatment

Clinical Snapshots


This AGA Clinical Snapshot is an executive summary of Dr. Sandborn's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.


1. Understand near-term and intermediate-term potential treatment options for patients who are failing currently available immunosuppressive and biologic therapy.

2. Many patients fail biologic therapy with anti-TNF agents and anti-integrin therapy with vedolizumab (anti-α4β7 antibody), through a variety of mechanisms including primary non-response, secondary lost response, and intolerance.

3. Treatment options switching within and out of class with alternative selective anti-integrin agents, sphingosine 1 phosphate (S1P) receptor modulators, Janus kinase (JAK) inhibitors, anti-interleukin 12/23 and anti- IL 23, and Smad7 antisense.

About the Instructors

William J. Sandborn, MD, AGAF, University of California, San Diego

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

What are the Future Selective Anti-integrin Therapies in Addition to the Currently Available Agent Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease?

In addition to the approved agent vedolizumab, there are three selective anti-integrin agents in development, anti-MAdCAM1 (PF-00547, 659, Pfizer), etrolizumab (anti-β7, rhumab beta 7, Genentech), anti-α4β7 (AMG181, Amgen) …

More on Crohn's Disease

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Building an IBD Specialty Clinic from the Ground Up

Feb. 7, 2018

Gastro One in Tennessee developed an IBD clinic within their practice, which decreased emergency room visits by 70 percent.

4 New & Noteworthy IBD Drug Studies

Jan. 30, 2018

We recommend reviewing these four abstracts from the Crohn’s & Colitis Congress to keep informed on IBD treatment options.